New combo aims to deepen remissions in rare blood cancer
NCT ID NCT07259122
First seen Dec 10, 2025 · Last updated May 10, 2026 · Updated 17 times
Summary
This study tests a combination of three drugs (zanubrutinib, a reduced dose of bendamustine, and a CD20 antibody) in 43 people with untreated Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if this approach can achieve a very good partial response or better. After four cycles of the combo, patients continue on zanubrutinib alone for eight months. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China, 300020, China
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.